Welcome to the Canadian National Multilingual News Group (CNMNG). This is a project made possible through funding by Canadian Heritage. CNMNG aims to gather news researched and written by a corps of Canadian-based journalists/writers from the country’s multilingual community groups. The overall goal is to inform, analyze and critique the issues of the day in a professional manner and to provide that to publishers and editors active in the ethnocultural-multilingual press and media whose experience provides them with a perspective that is sensitive to news relevant to their own language group.
Photo courtesy of ICIJ
Five years after the Panama Papers, the fight against offshore crime has a long way to go. Governments around the world have recovered more than $1.36 billion in back taxes and penalties, including $185 million in the last 2 years; however, the recovery in Canada is very low. →
[GTranslate]Often the best stories start by chance. Maybe due to a series of coincidences, a chance encounter, an intuition. →
ROME – Bringing Italian and Canadian entrepreneurs and workers closer together as easily and quickly as possible, even in times of Covid. →
ROMA – Avvicinare nel modo più agevole e veloce possibile imprenditori e lavoratori italiani e canadesi, anche in tempi di Covid. È una delle nuove, principali sfide della Canadian Chamber in Italy, associazione no profit attiva da anni a Roma, che oggi è pronta a rilanciare la sua attività con un direttivo rafforzato, a cominciare dalla nuova presidente Caterina Passariello – volto emergente tra i più promettenti nel mondo della giovane imprenditoria e project manager della società di consulenza alle imprese “Euromed International Trade” – ed il vicepresidente Domenico Letizia, giornalista e analista casertano tra i più attivi autori di ricerche e approfondimenti sulla blue economy, la pesca e la geopolitica canadese (nelle foto in alto, la presidente ed il vice). →
Toronto, April 16: The first clinical trial of the Covid-19 vaccine made in Canada has been conducted. Developed by University of Alberta researcher and CEO of Entos Pharmaceuticals, Dr. John Lewis, the phase 1 of the clinical trial of that vaccine has been applied to the human body yesterday. →
